Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01790958
Other study ID # RIH 1009
Secondary ID
Status Completed
Phase N/A
First received February 11, 2013
Last updated February 11, 2013
Start date June 2012
Est. completion date December 2012

Study information

Verified date February 2013
Source Retina Institute of Hawaii
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Microcurrent stimulation thereapy improves retinal efficiency and may restore and/or improve retinal function.


Description:

This is an observational study in which data will be collected from a group of patients with retinal diseases such as Dry Macular Degeneration, RetinitisPigmentosa, and Stargardt's Disease, who have opted to receive Microcurrent Stimulation Therapy as an alternative treatment for their retinal condition.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Ability to provide written consent and comply with follow up visits

- Age 40 years or older

- ETDRS best corrected visual acuity better than 5 letters

- History of Dry Age Relted Macular Degeneration; Retinitis Pigmentosa; Stargardt's disease

- No Anti-VEGF treatments for at least 3 months prior to study

- No new antioxidant/vitamin supplementation for at least 3 months prior to study

Exclusion Criteria:

- History of Non-Compliance with regular medical visits

- Significant media opacities (exclude NS 4+) that may interfere with assessing visual acuity

- Presence of pigment epithelial tears or rips

- Known serious allergies to fluorescein dye

- Presence of retinal neovascularization

- Any treatment with an investigation agent in the past 30 days

Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Locations

Country Name City State
United States Hawaii Cataract Laser Institute - Hilo Hilo Hawaii
United States Retina Institute of Hawaii Honolulu Hawaii
United States Hawaii Cataract Laser Institute - Maui Kahului Hawaii
United States Hawaii Cataract Laser Institute - Kona Kailua-Kona Hawaii

Sponsors (1)

Lead Sponsor Collaborator
Retina Institute of Hawaii

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure visual acuity after receiving microcurrent stimulation treatments. 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2